Stuart Brill
Neurology · Valhalla, NYNPI 1063998268
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 53 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by UCB, Inc. at 39.0% of the total. Reporting peaked in 2019 at $596 and has fallen 81.2% since, to $112 in 2025.
Across 53 payments — averaging $29.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$609
- Alnylam Pharmaceuticals Inc.$156
- MDD US Operations, LLC$137
- Neurocrine Biosciences, Inc.$113
- Acorda Therapeutics, Inc$68
- CSL Behring$65
- plus $415 from 17 others
What the payments were for
- Food & beverage$1,564100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 18 | $609 |
| Alnylam Pharmaceuticals Inc. | 2 | $156 |
| MDD US Operations, LLC | 3 | $137 |
| Neurocrine Biosciences, Inc. | 5 | $113 |
| Acorda Therapeutics, Inc | 1 | $68 |
| CSL Behring | 3 | $65 |
| Microvention, Inc. | 1 | $40 |
| Avanir Pharmaceuticals, Inc. | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| Merck | 2 | $31 |
| Vertical Pharmaceuticals, LLC | 2 | $31 |
| Biohaven Pharmaceuticals, Inc. | 1 | $29 |
| Stryker | 1 | $28 |
| Lilly USA, LLC | 2 | $28 |
| Sanofi | 1 | $26 |
| Lundbeck LLC | 1 | $22 |
| Amgen | 1 | $21 |
| Argenx US, Inc. | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Acadia Pharmaceuticals Inc | 1 | $15 |
| Aquestive Therapeutics, Inc. | 1 | $15 |
| AstraZeneca | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,564 in reported general payments places this provider in the 55th percentile of 1,623 neurology providers in New York.
Other neurology in Valhalla
- Fawaz Al MuftiValhalla$367K
- Idan SharonBrooklyn$2.1M
- Allan PerelStaten Island$1.7M
- Nicolas SaikaliAmherst$1.5M
- David KreitzmanCommack$1.5M
- Charles ArgoffAlbany$1.2M
- Stephen KriegerNew York$1.1M
- Robert FeketeHawthorne$1M
- Jennifer McVigeAmherst$982K
- Warren SpinnerPort Jefferson Station$791K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.